Regorafenib：轉移性大腸直腸癌與胃腸道基質瘤之口服標靶藥物

針對腫瘤細胞特異性的標靶治療，能夠抑制腫瘤生長及擴散，不僅具有良好的抗癌效果，也能減少對於正常細胞的傷害，已然成為目前癌症治療的趨勢。Regorafenib 是一個口服小分子多重標靶藥物，臨床上應用於治療轉移性大腸直腸癌及胃腸道基質瘤。作為其他藥物治療下發生疾病惡化或無法耐受時的後線藥物，regorafenib 能顯著改善轉移性大腸直腸癌病人的整體存活時間及無疾病惡化時間，用於胃腸道基質瘤亦能有效增加無疾病惡化時間。針對亞洲人進行的試驗則發現亞洲人發生手足皮膚反應及肝臟不良反應的機會較高。成本效果的數據分析顯示regorafenib 用於轉移性大腸直腸癌僅增加少許的益處但卻需付出很高的成本，而用於胃腸道基質瘤則符合成本效果。

Specifically targeting cancer cell biology, targeted therapy provides antitumor activity with limited harm to normal tissues. Targeted therapy has become a pivotal therapy for various malignancies. Regorafenib, an oral small-molecule multi-targeted kinase inhibitor, has been approved as late line therapy for metastatic colorectal cancer and gastrointestinal stromal tumors. In phase 3 clinical trials, regorafenib has been shown to significantly prolong overall and progression-free survival for patients with metastatic colorectal cancer and prolong progression-free survival for patients with metastatic GIST. Asian patients have higher rates of hand-foot skin reaction and hepatic adverse reactions. Cost-effectiveness analyses showed that regorafenib provides limited benefits with high costs for metastatic colorectal cancer, but is a cost-effective treatment for GIST.